{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T12:46:02Z","timestamp":1770554762975,"version":"3.49.0"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024619","name":"Ohio Attorney General's Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA033934"],"award-info":[{"award-number":["P30DA033934"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3DA050311"],"award-info":[{"award-number":["UH3DA050311"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction Biology"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Here, we present recent studies suggesting that specific <jats:italic>DRD3<\/jats:italic> single nucleotide polymorphisms (SNPs, e.g. rs324029 and rs2654754) might serve as prognostic biomarkers for opioid use disorder (OUD). Additionally, preclinical studies with novel dopamine 3 receptor (D3R) partial agonists and antagonists have been evaluated as candidate OUD therapeutics and have shown a reduced risk of cardiovascular toxicity compared with the original D3R antagonist. From these findings, we argue that <jats:italic>DRD3<\/jats:italic> SNPs could serve as a diagnostic tool for assessing OUD risk and that more research is warranted examining the D3R as a safe and effective therapeutic target for treating OUD.<\/jats:p>","DOI":"10.1111\/adb.13369","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T01:49:15Z","timestamp":1706492955000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder"],"prefix":"10.1111","volume":"29","author":[{"given":"Matthew L.","family":"Banks","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0349-5072","authenticated-orcid":false,"given":"Jon E.","family":"Sprague","sequence":"additional","affiliation":[{"name":"The Ohio Attorney General's Center for the Future of Forensic Science Bowling Green State University  Bowling Green Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.02.020"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2022_347"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.12\u201002\u201000483.1992"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3939"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006\u20108993(97)01078\u20100"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2013.12.018"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397\u2010021\u201000212\u20100"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2864"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.145"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.08.016"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.04.003"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386\u2010023\u201001590\u20108"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addicn.2023.100065"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00607"},{"key":"e_1_2_5_17_1","unstructured":"KampmanK.Cariprazine for comorbid cocaine and opioid use disorders.ClinicalTrails.govaccess date Sept 28 2023.https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05063201"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.259390"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.085472"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.214833"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386\u2010019\u20100336\u20105"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"}],"container-title":["Addiction Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/adb.13369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T08:14:45Z","timestamp":1733386485000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/adb.13369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/adb.13369"],"URL":"https:\/\/doi.org\/10.1111\/adb.13369","archive":["Portico"],"relation":{},"ISSN":["1355-6215","1369-1600"],"issn-type":[{"value":"1355-6215","type":"print"},{"value":"1369-1600","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]},"assertion":[{"value":"2023-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13369"}}